Cardiff University

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Gilead Gets Xilio’s Phase I Cancer Drug

The University of Texas MD Anderson Cancer Center and US/UK biotech Replay announced on 14 February that they are launching a new company, Syena, to advance research conducted at the cancer center o

Cardiff Oncology, Inc. presented updates from the ongoing Phase Ib/II clinical trial for its Polo-like kinase-1 (PLK1) inhibitor onvansertib at the European Society for Medical Oncology (ESMO) meetin

Below is Scrip’s regular roundup, including information from Strategic Transactions , of recent technology transfer agreements and collaborations between companies and academic or other research inst